What are LNPs?
Lipid nanoparticles (LNPs) are spherical nanostructures composed of ionizable lipids, phospholipids, cholesterol, and PEG-modified lipids. Compared to traditional cationic lipid or polymer carriers, this structure carries a smaller charge at neutral pH, significantly reducing cytotoxicity; while in acidic environments (such as endosomes), the charge is restored, facilitating endosomal escape and nucleic acid release.
Figure 1. Schematic diagram of LNPs for RNA delivery. a. LNPs formulated from various lipid components and mRNA. b. Cellular uptake of LNPs, including endocytosis, endosomal escape, LNP degradation, and mRNA release into the cytosol[1].
This design makes LNPs a highly biocompatible, efficient, and scalable nucleic acid delivery platform, ideal for transfection and gene editing experiments of molecules such as mRNA, siRNA, shRNA, CRISPR gRNA, and Cas9 mRNA in vitro and in vivo.
Why Choose LNP Instead of Traditional Transfection Methods?
- Low toxicity and high safety: Because ionizable lipids are neutral at physiological pH, they reduce the strong disruption of the cell membrane caused by traditional cationic lipids (lipofection), thus protecting cell viability.
- High transfection efficiency and stable expression: LNP can achieve more stable and sustained nucleic acid expression, performing particularly well in high-throughput screening (96-well/384-well plates) or CRISPR editing experiments.
- Simple operation: Using the LipoSwift LNP platform, efficient delivery can be achieved without complex electroporation instruments or viral vectors, simplifying the workflow.
- Strong scalability: The LNP formulation platform itself is highly flexible and can be used for early screening, target optimization, and eventual large-scale production.
Figure 2. (A) Schematic diagram of LNP encapsulating barcoded plasmid DNA used for accelerating in vivo delivery screening and lead compound identification. (B) Schematic diagram of LNP-based DNA vaccine immunization. (C) Darker clusters indicate higher delivery levels, while lighter clusters indicate lower delivery levels. (D, E) Bar graphs showing the percentage of LNP delivery in different target tissues 4 hours after intramuscular injection[2].
What is LipoSwift LNP In Vitro Cell Transfection Kit?
Alfa Chemistry's LipoSwift LNP In Vitro Cell Transfection Kit is a lipid nanoparticle delivery system specifically designed for in vitro cell transfection. This kit utilizes LNP technology for one-step encapsulation, requiring no special equipment; users can complete the process using only standard laboratory pipetting techniques.
It is compatible with a wide range of cell types, including cell lines, primary cells, high-throughput screening platforms, and even the combination of Cas9 mRNA + gRNA used in CRISPR gene editing experiments. Compared to traditional liposome or electroporation methods, this kit demonstrates lower cytotoxicity, higher stable expression, and better ease of use.
For more LipoSwift series reagent kit products, please click here.
How to Use the LipoSwift LNP In Vitro Kit for In Vitro Transfection?
The following is a suggested protocol to help researchers efficiently utilize this kit:
A. Prepare Nucleic Acid Payload
Dissolve the nucleic acid (mRNA, siRNA, Cas9 mRNA + gRNA, etc.) in a suitable buffer (e.g., acidic buffer to ensure binding with ionizable lipids) according to experimental needs.
B. LNP Encapsulation
Mix the organic phase containing lipid components (ionizable lipids, cholesterol, phospholipids, and PEG lipids) with the aqueous nucleic acid phase to complete encapsulation in one step. The LipoSwift platform is designed to make this process simple, requiring no specialized equipment.
C. Purification and Characterization
Measure the particle size and polydispersity index (PDI) of the LNPs using techniques such as dynamic light scattering (DLS) to verify that the particle size is within the ideal range (e.g., 20–200 nm).
D. Cell Plating
Quantify encapsulation efficiency through encapsulation rate detection.
E. Cell Plating
Select an appropriate cell density (e.g., approximately 5×104 cells/well in a 24-well plate for HEK-293T cells) and culture until compatible with transfection.
F. Transfection
Add the prepared LNP suspension directly to the cell culture system; no special electroporation procedure is required.
G. Evaluate Expression and Toxicity
After transfection, sample at different time points (e.g., 24h, 48h) and evaluate expression efficiency using methods such as fluorescence microscopy, quantitative PCR, or reporter genes. Simultaneously monitor cell viability (e.g., MTT, CCK-8) to verify low toxicity characteristics.
Scientific Principles Behind LNP System Efficiency and Mechanisms
How do LNPs achieve efficient delivery?
- Endosomal escape: Ionizable lipids are protonated in acidic environments, promoting interaction with the endosomal membrane and disrupting the endosomal structure, thereby releasing nucleic acids into the cytoplasm.
- PEG-lipid stabilization: PEGylated lipids provide stability during the initial formulation, reducing particle aggregation and controlling particle size and circulation properties (if applied in vivo).
- Structural composition optimization: Cholesterol and phospholipids provide stability and fluidity to the LNP's bilayer structure, optimizing encapsulation efficiency and particle size distribution.
Figure 3. The mechanisms of pH-sensitive amphiphilic membrane disruption and endosomal escape of non-lamellar ionizable lipid nanoparticles after endocytosis[3].
How does LNP formulation optimization affect transfection efficiency?
Researchers typically use Design of Experiments (DOE) methods to systematically screen different formulations (e.g., ionizable lipid ratio, cholesterol ratio, PEG ratio, etc.) to achieve high-efficiency, low-toxicity mRNA delivery in specific cell types (e.g., T cells).
Similarly, formulation structure (e.g., lipid ratio, RB/I ratio) significantly affects the morphological stability and transfection performance of LNPs.
Furthermore, theoretical and computational modeling (mechanistic modeling) is also widely used to understand the LNP formation process (e.g., diffusion, mixing kinetics) and its correlation with key quality attributes (particle size, PDI, encapsulation efficiency, stability, etc.), thereby guiding formulation and process optimization.
Summary
Alfa Chemistry's LipoSwift LNP in vitro cell transfection kit represents a modern, efficient, and safe solution for in vitro gene delivery technology. It integrates the core advantages of LNPs—low toxicity, high efficiency, ease of operation, and high flexibility—making it a powerful tool for research applications such as transfection, gene editing (CRISPR), and functional screening. For laboratories dedicated to nucleic acid drug development, gene editing technology optimization, or basic biological research, this kit not only simplifies workflows but also significantly improves experimental success rate and reproducibility.
References
- Barot S., et al. Recent advancement in targeted therapy and role of emerging technologies to treat cancer. Medical Oncology. 2023, 40(11), 324.
- Guimaraes LC., et al. Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models. Nature Communications. 2024, 15, 590.
- Lu Z-R., et al. Mechanism of pH-sensitive Amphiphilic Endosomal Escape of Ionizable Lipid Nanoparticles for Cytosolic Nucleic Acid Delivery. Pharmaceutical Research. 2025, 42, 1065-1077.
Our products and services are for research use only and cannot be used for any clinical purposes.
